These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17447418)

  • 1. The relationship of early studies of monoamine oxidase to present concepts.
    Kopin IJ
    J Neural Transm Suppl; 2006; (71):79-86. PubMed ID: 17447418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
    Binda C; Milczek EM; Bonivento D; Wang J; Mattevi A; Edmondson DE
    Curr Top Med Chem; 2011 Nov; 11(22):2788-96. PubMed ID: 22039878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
    Youdim MB; Bakhle YS
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. History and therapeutic use of MAO-A inhibitors: a historical perspective of mao-a inhibitors as antidepressant drug.
    Yáñez M; Padín JF; Arranz-Tagarro JA; Camiña M; Laguna R
    Curr Top Med Chem; 2012; 12(20):2275-82. PubMed ID: 23231399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
    Tripathi AC; Upadhyay S; Paliwal S; Saraf SK
    Eur J Med Chem; 2018 Feb; 145():445-497. PubMed ID: 29335210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
    Kumar B; Gupta VP; Kumar V
    Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
    Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
    Tripathi RKP; Ayyannan SR
    Med Res Rev; 2019 Sep; 39(5):1603-1706. PubMed ID: 30604512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.
    Chaurasiya ND; Leon F; Muhammad I; Tekwani BL
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M; Sanz E
    Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential.
    Dhiman P; Malik N; Khatkar A
    Comb Chem High Throughput Screen; 2017; 20(6):474-491. PubMed ID: 28413973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
    Delumeau JC; Bentué-Ferrer D; Gandon JM; Amrein R; Belliard S; Allain H
    J Neural Transm Suppl; 1994; 41():259-66. PubMed ID: 7931235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Curr Top Med Chem; 2012; 12(20):2177-88. PubMed ID: 23231395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on amine oxidase inhibitors: multifaceted drugs.
    Song MS; Matveychuk D; MacKenzie EM; Duchcherer M; Mousseau DD; Baker GB
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():118-24. PubMed ID: 23410524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.